I have an upcoming episode with Dr
FDA-approved products containing semaglutide and tirzepatide are available
Retatrutide Research Peptide Retatrutide is a synthetic triple hormone receptor agonist peptide developed by Eli Lilly the first-in-class compound to simultaneously activate GLP-1, GIP, and glucagon receptors
Some patients benefit from combined approachesbehavioral coaching plus medicationwhile others achieve goals through medication alone, or through structured behavioral programs without pharmacotherapy
5 Pharmacological effects of GIP, GLP-1 and their mimetics The pharmacological benefits of GIP, GLP-1, and their synthetic mimetics arise from their pleiotropic effects, encompassing at least five key functions: bolstering insulin secretion and survival of pancreatic -cells and modulating glucagon release by the pancreatic -cells in response to glycemic levels, acting on the satiety center in brain, slowing gastric emptying, regulating lipid and glucose metabolism through effects on adipose tissue and liver, and reducing systemic blood pressure
The American Diabetes Association recommends reassessing glycemic control within 3 months of any significant medication change
